Distribution of PSA velocity by total PSA levels: Data from the Baltimore Longitudinal study of aging

Stacy Loeb, H. Ballentine Carter, Edward M. Schaeffer, Anna Kettermann, Luigi Ferrucci, E. Metter

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: To describe the distribution and implications of prostate-specific antigen velocity (PSAV) by prostate-specific antigen (PSA) in an unselected population. A PSAV >0.35 and >2.0 ng/mL/y have been associated with an increased risk of prostate cancer (CaP) death more than 10 years and 1 year before diagnosis, respectively. It is unknown how frequently PSAVs of this magnitude occur in community men. Methods: From the Baltimore Longitudinal Study of Aging, we examined the PSAV distribution in 786 men with serial PSA measurements (3474 PSAV observations) at total PSA levels <10 ng/mL. We also determined whether PSAV altered the probability of overall and life-threatening CaP at PSA levels <3 and 3-10 ng/mL. Results: Overall, the mean PSA and PSAV were 1.3 ng/mL and 0.05 ng/mL/y, respectively. PSAV rose continuously with increasing PSA (P <.0001), and was significantly higher in cancers than controls for observations at PSA levels <3 ng/mL (P = .02) and 3-10 ng/mL (P = .0008). The probability of life-threatening CaP was 3% at a PSA <3 ng/mL, but increased to 13.6% with PSAV >0.4 ng/mL/y. At PSA levels of 3-10 ng/mL, the probability of life-threatening CaP was 9.8% based on PSA alone vs 12% with PSAV >0.4 ng/mL/y. Conclusions: PSAV was significantly higher in CaP observations than controls in all PSA ranges studied and altered the risk of overall and life-threatening CaP at a given PSA level. Because the value of PSAV is PSA-dependent, the PSA level should be taken into account when interpreting PSAV.

Original languageEnglish (US)
Pages (from-to)143-147
Number of pages5
JournalUrology
Volume77
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Baltimore
Prostate-Specific Antigen
Longitudinal Studies

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Distribution of PSA velocity by total PSA levels : Data from the Baltimore Longitudinal study of aging. / Loeb, Stacy; Carter, H. Ballentine; Schaeffer, Edward M.; Kettermann, Anna; Ferrucci, Luigi; Metter, E.

In: Urology, Vol. 77, No. 1, 01.01.2011, p. 143-147.

Research output: Contribution to journalArticle

Loeb, Stacy ; Carter, H. Ballentine ; Schaeffer, Edward M. ; Kettermann, Anna ; Ferrucci, Luigi ; Metter, E. / Distribution of PSA velocity by total PSA levels : Data from the Baltimore Longitudinal study of aging. In: Urology. 2011 ; Vol. 77, No. 1. pp. 143-147.
@article{8a99262bcb9943f99bc2507192994b49,
title = "Distribution of PSA velocity by total PSA levels: Data from the Baltimore Longitudinal study of aging",
abstract = "Objectives: To describe the distribution and implications of prostate-specific antigen velocity (PSAV) by prostate-specific antigen (PSA) in an unselected population. A PSAV >0.35 and >2.0 ng/mL/y have been associated with an increased risk of prostate cancer (CaP) death more than 10 years and 1 year before diagnosis, respectively. It is unknown how frequently PSAVs of this magnitude occur in community men. Methods: From the Baltimore Longitudinal Study of Aging, we examined the PSAV distribution in 786 men with serial PSA measurements (3474 PSAV observations) at total PSA levels <10 ng/mL. We also determined whether PSAV altered the probability of overall and life-threatening CaP at PSA levels <3 and 3-10 ng/mL. Results: Overall, the mean PSA and PSAV were 1.3 ng/mL and 0.05 ng/mL/y, respectively. PSAV rose continuously with increasing PSA (P <.0001), and was significantly higher in cancers than controls for observations at PSA levels <3 ng/mL (P = .02) and 3-10 ng/mL (P = .0008). The probability of life-threatening CaP was 3{\%} at a PSA <3 ng/mL, but increased to 13.6{\%} with PSAV >0.4 ng/mL/y. At PSA levels of 3-10 ng/mL, the probability of life-threatening CaP was 9.8{\%} based on PSA alone vs 12{\%} with PSAV >0.4 ng/mL/y. Conclusions: PSAV was significantly higher in CaP observations than controls in all PSA ranges studied and altered the risk of overall and life-threatening CaP at a given PSA level. Because the value of PSAV is PSA-dependent, the PSA level should be taken into account when interpreting PSAV.",
author = "Stacy Loeb and Carter, {H. Ballentine} and Schaeffer, {Edward M.} and Anna Kettermann and Luigi Ferrucci and E. Metter",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.urology.2010.04.068",
language = "English (US)",
volume = "77",
pages = "143--147",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Distribution of PSA velocity by total PSA levels

T2 - Data from the Baltimore Longitudinal study of aging

AU - Loeb, Stacy

AU - Carter, H. Ballentine

AU - Schaeffer, Edward M.

AU - Kettermann, Anna

AU - Ferrucci, Luigi

AU - Metter, E.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objectives: To describe the distribution and implications of prostate-specific antigen velocity (PSAV) by prostate-specific antigen (PSA) in an unselected population. A PSAV >0.35 and >2.0 ng/mL/y have been associated with an increased risk of prostate cancer (CaP) death more than 10 years and 1 year before diagnosis, respectively. It is unknown how frequently PSAVs of this magnitude occur in community men. Methods: From the Baltimore Longitudinal Study of Aging, we examined the PSAV distribution in 786 men with serial PSA measurements (3474 PSAV observations) at total PSA levels <10 ng/mL. We also determined whether PSAV altered the probability of overall and life-threatening CaP at PSA levels <3 and 3-10 ng/mL. Results: Overall, the mean PSA and PSAV were 1.3 ng/mL and 0.05 ng/mL/y, respectively. PSAV rose continuously with increasing PSA (P <.0001), and was significantly higher in cancers than controls for observations at PSA levels <3 ng/mL (P = .02) and 3-10 ng/mL (P = .0008). The probability of life-threatening CaP was 3% at a PSA <3 ng/mL, but increased to 13.6% with PSAV >0.4 ng/mL/y. At PSA levels of 3-10 ng/mL, the probability of life-threatening CaP was 9.8% based on PSA alone vs 12% with PSAV >0.4 ng/mL/y. Conclusions: PSAV was significantly higher in CaP observations than controls in all PSA ranges studied and altered the risk of overall and life-threatening CaP at a given PSA level. Because the value of PSAV is PSA-dependent, the PSA level should be taken into account when interpreting PSAV.

AB - Objectives: To describe the distribution and implications of prostate-specific antigen velocity (PSAV) by prostate-specific antigen (PSA) in an unselected population. A PSAV >0.35 and >2.0 ng/mL/y have been associated with an increased risk of prostate cancer (CaP) death more than 10 years and 1 year before diagnosis, respectively. It is unknown how frequently PSAVs of this magnitude occur in community men. Methods: From the Baltimore Longitudinal Study of Aging, we examined the PSAV distribution in 786 men with serial PSA measurements (3474 PSAV observations) at total PSA levels <10 ng/mL. We also determined whether PSAV altered the probability of overall and life-threatening CaP at PSA levels <3 and 3-10 ng/mL. Results: Overall, the mean PSA and PSAV were 1.3 ng/mL and 0.05 ng/mL/y, respectively. PSAV rose continuously with increasing PSA (P <.0001), and was significantly higher in cancers than controls for observations at PSA levels <3 ng/mL (P = .02) and 3-10 ng/mL (P = .0008). The probability of life-threatening CaP was 3% at a PSA <3 ng/mL, but increased to 13.6% with PSAV >0.4 ng/mL/y. At PSA levels of 3-10 ng/mL, the probability of life-threatening CaP was 9.8% based on PSA alone vs 12% with PSAV >0.4 ng/mL/y. Conclusions: PSAV was significantly higher in CaP observations than controls in all PSA ranges studied and altered the risk of overall and life-threatening CaP at a given PSA level. Because the value of PSAV is PSA-dependent, the PSA level should be taken into account when interpreting PSAV.

UR - http://www.scopus.com/inward/record.url?scp=78650884730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650884730&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2010.04.068

DO - 10.1016/j.urology.2010.04.068

M3 - Article

C2 - 21195835

AN - SCOPUS:78650884730

VL - 77

SP - 143

EP - 147

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -